technology

fitness

The 9 Fitness Technology Gifts To Add to Your List, Stat

As far as I’m concerned, we’re all living in The Jetsons—except, rather than casually owning flying cars, we’re all flying on techy treads, strapping devices that measure our heart rates on our wrists, and taking yoga classes from a magic mirror on the wall. The future is now, folks. So if you have someone on your holiday list who lives the sweat life, we’ve rounded up the best fitness technology buys you can wrap in a bow and feel confident they’ll love.

From smartwatches to wireless earbuds to next-level recovery devices, we’ve rounded up the gifts that just keep on giving—many of which are on sale right now. You can’t go wrong no matter which one you choose, so let’s get shopping, shall we?

Photo: FitbitThe Fitbit Versa 3 arrives packed with cool features. Perhaps most notably, the device records your “active zone minutes” that buzz when you reach your desired heart rate during exercise. That means when the burpees hit just right, you’ll get a little buzz to say “good job.”

Shop now:  Fitbit Versa 3, $230

Photo: Peloton

There are few things I wouldn’t do to own this treadmill. After running on one years ago at the Peloton Tread+ studio in New York City, I instantly started a “Peloton” fund to save up for the day when I would purchase this baby and run it into the sunset. Alas, I’m still saving—but we’ll get there. One of the techy features that makes this treadmill all the rage is the fact that you can use easy-access knobs to adjust your speed and incline in seconds, but there’s so much more in store, fam.

Shop now: Peloton Tread, $2,495

Photo: Amazon

Ah, the Airpods Pro. I’ve written about them so many times because they are worth every word. With noise-cancellation that literally transplants you to a new world, nothing will disrupt your workouts ever again.

Shop now: Apple Airpods Pro, $250

Photo: JAXJOX

Who needs five different kettlebells when you could just buy one adjustable one? This device can adapt from weighing 12 pounds to 42 in less than three seconds and uses artificial intelligence reporting to record your reps, sets, and workout as a whole.

Shop now: JAXJOX Kettlebell Connect 2.0, $199

Photo: Powerdot

When you gift someone a Powerdot, you’re gifting them a future of home massages. Just strap it onto any sore muscle group and you’ll feel its Smart Muscle Stimulator get to work on repairing those muscles so you can get out for your run, bike ride, or HIIT workout again soon.

Shop now:  Powerdot 2.0, $199

Photo: Oura

Ask any expert—a trainer, a makeup artist, a sleep doctor—and they’ll tell you that eight hours of sleep is essential for doing all the things you love. The Oura Ring pays attention while you sleep and delivers a morning report that gives you the 411 on your slumber.

Shop now: Oura Ring, $299

Photo: Sonos

At-home workouts turn studio-level when you add this Sonos speaker.

Read More
fitness

Wearable Fitness Electronics and Technology Market : Key Facts and Forecast Predictions Presented

The MarketWatch News Department was not involved in the creation of this content.

Nov 20, 2020 (AmericaNewsHour) —
Kenneth Research has published a detailed report on Wearable Fitness Electronics and Technology Market which has been categorized by market size, growth indicators and encompasses detailed market analysis on macro trends and region-wise growth in North America, Latin America, Europe, Asia-Pacific and Middle East & Africa region. The report also includes the challenges that are affecting the growth of the industry and offers strategic evaluation that is required to boost the growth of the market over the period of 2017-2025.

According to the statistics by the GSM Association, 1.8 billion 5G connections are to be registered by 2025. The market is segmented by various factors into SEGMENTS. The report further contains detailed assessment of each of the segment.

“THE FINAL REPORT WILL COVER THE IMPACT ANALYSIS OF COVID-19 ON THIS INDUSTRY.”

Click Here to Download Sample Report >> https://www.kennethresearch.com/sample-request-10338009

Summary

This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.

The report includes as follows:
The report provides current data, historical overview and future forecast.
The report includes an in-depth analysis of the Global market for Wearable Fitness Electronics and Technology , covering Global total and major region markets.
The data of 2017-2025 are included. All-inclusive market are given through data on sales, consumption, and prices (Global total and by major regions).
The report provides introduction of leading Global manufacturers.
Wearable Fitness Electronics and Technology market prospects to 2025 are included (in sales, consumption and price).

Market Segment as follows:
By Region / Countries
*North America (U.S., Canada, Mexico)
*Europe (Germany, U.K., France, Italy, Russia, Spain etc)
*Asia-Pacific (China, India, Japan, Southeast Asia etc)
*South America (Brazil, Argentina etc)
*Middle East & Africa (Saudi Arabia, South Africa etc)

By Type
*Smartwatch 
*Headband/Smartcap 
*Smart shirt/jacket 
*Smartshoe 
*Others

By End-User / Application
*Handwear 
*Legwear 
*Headwear 
*Others

By Company
*Adidas AG 
*Apple 
*Fitbit 
*Garmin 
*Google 
*LG Electronics 
*Samsung 
*Sony 
*Nike 

In the statistics by Eurostat, the total value of the ICT sector including manufacturing and services of ICT in Europe, was estimated to be more than EUR 475 billion in the year 2017. Out of these, the ICT services sector accounted for the largest share. Moreover, the ICT services sector is predicted to be ten times larger than that of ICT manufacturing. On the other hand, the ICT services consist of computer programming, consultancy and related activities, along with telecommunication activities, out of which the former held about 49.1% share while the latter held around 30.3% share in the year 2017. These factors are estimated to impact positively towards the growth of the market in the next few years.

The Information and Communications Technologies (ICT) sector in Canada consists of more than 41,500 companies, out of which, over 37,000 companies come under the category of software and computer services

Read More
fitness

Interactive Fitness Market 2020-2024- Featuring Axtion Technology LLC, EGYM Inc., among others to contribute to the market growth | Industry Analysis, Market Trends, Opportunities and Forecast 2024

LONDON–(BUSINESS WIRE)–The interactive fitness market is poised to grow by USD 4.81 bn during 2020-2024, progressing at a CAGR of almost 7% during the forecast period.

Worried about the impact of COVID-19 on your Business? Here is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.

Get FREE Sample Report in Minutes!

The report on the interactive fitness market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the growing awareness among people about fitness and a healthy lifestyle.

The interactive fitness market analysis includes end-user segment and geography landscape. This study identifies the adoption of fitness-related initiatives by corporates as one of the prime reasons driving the interactive fitness market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The interactive fitness market covers the following areas:

Interactive Fitness Market Sizing

Interactive Fitness Market Forecast

Interactive Fitness Market Analysis

Companies Mentioned

  • Axtion Technology LLC
  • Echelon Fitness Multimedia LLC
  • EGYM Inc.
  • Motion Fitness LLC
  • Nautilus Inc.
  • Nexersys Corp.
  • Paradigm Health and Wellness Inc.
  • Peloton Interactive Inc.
  • TECHNOGYM Spa
  • Tonal Systems Inc.

Related Reports on Consumer Discretionary Include:

  • Massage Equipment Market by Product, End-user, Type, and Geography – Forecast and Analysis 2020-2024– The massage equipment market size has the potential to grow by USD 3.27 billion during 2020-2024, and the market’s growth momentum will accelerate during the forecast period. To get extensive research insights: Click and get FREE sample report in minutes
  • Water Heater Market by End-user, Distribution Channel, Type, and Geography – Forecast and Analysis 2020-2024– The water heater market size has the potential to grow by USD 2.76 billion during 2020-2024, and the market’s growth momentum will accelerate during the forecast period. To get extensive research insights: Click and get FREE sample report in minutes

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market Outlook
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY END-USER

  • Market segmentation by end-user
  • Comparison by end-user
  • Non-residential – Market size and forecast 2019-2024
  • Residential – Market size and forecast 2019-2024
  • Market opportunity by end-user

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • APAC – Market size and forecast 2019-2024
  • South America – Market size and forecast
Read More
medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Source Article

Read More
medicine

TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine

SEATTLE, Nov. 18, 2020 /PRNewswire/ — TwinStrand Biosciences today announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction technology. Duplex Sequencing increases the accuracy of next-generation sequencing as much as 10,000 times, allowing the detection of ultra-low frequency mutations that would otherwise be hidden by technical noise inherent to the sequencing process.

“Staying at the forefront of innovative solutions to advance cancer care is central to our commitment to patients,” said Cindy Perettie, chief executive officer at Foundation Medicine. “We are excited to partner with TwinStrand to support doctors in making genomically-informed treatment decisions.”

“This agreement validates the strength of TwinStrand’s technology and intellectual property portfolio,” said Dr. Jesse Salk, chief executive officer at TwinStrand Biosciences. “We are pleased that Foundation Medicine has partnered with us to use our patented technology to achieve the highest possible performance for liquid biopsy testing.”

About TwinStrand Biosciences
TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.twinstrandbio.com.

About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG). Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Media Contact:
[email protected]

SOURCE TwinStrand Biosciences

Related Links

http://www.twinstrandbio.com

Source Article

Read More
medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences – Press Release

CAMBRIDGE, Mass.–(Business Wire)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Lee-Ann Murphy, 617-245-3077

[email protected]

Abigail Alderman, 781-534-3210

[email protected]

// Load the SDK Asynchronously (function(d){ var js, id = 'facebook-jssdk', ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) {return;} js = d.createElement('script'); js.id = id; js.async = true; js.src = "http://connect.facebook.net/en_US/all.js"; ref.parentNode.insertBefore(js, ref); })(document); })();

Source Article

Read More
medicine

Global Sports Medicine Device Market to 2025 – by Manufacturers, Regions, Technology, and Product Type

DUBLIN, Nov. 10, 2020 /PRNewswire/ — The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Key points of Sports Medicine Device Market Report:
1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for each company.
3. The report depicts the global and Chinese total Sports Medicine Device market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
4. The global Sports Medicine Device market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5. The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of Sports Medicine Device market.
6. The report makes some important proposals for a new project of Sports Medicine Device Industry before evaluating its feasibility.
7. Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Sports Medicine Device market covering all important parameters.

Key Topics Covered:

1.: Introduction of Sports Medicine Device Industry
1.1 Brief Introduction of Sports Medicine Device
1.2 Development of Sports Medicine Device Industry
1.3 Status of Sports Medicine Device Industry

2.: Manufacturing Technology of Sports Medicine Device
2.1 Development of Sports Medicine Device Manufacturing Technology
2.2 Analysis of Sports Medicine Device Manufacturing Technology
2.3 Trends of Sports Medicine Device Manufacturing Technology

3.: Analysis of Global Key Manufacturers
3.1 Arthrex
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 Capacity Production Price Cost Production Value
3.1.4 Contact Information
3.2 Smith & Nephew
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 Capacity Production Price Cost Production Value
3.2.4 Contact Information
3.3 Stryker
3.3.1 Company Profile
3.3.2 Product Information
3.3.3 Capacity Production Price Cost Production Value
3.3.4 Contact Information
3.4 Depuy Synthes/Johnson & Johnson
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 Capacity Production Price Cost Production Value
3.4.4 Contact Information
3.5 Zimmer Biomet
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 Capacity Production Price Cost Production Value
3.5.4 Contact Information
3.6 Karl Storz
3.6.1 Company Profile
3.6.2 Product Information
3.6.3 Capacity Production Price Cost Production Value
3.6.4 Contact Information
3.7 Conmed
3.7.1 Company Profile
3.7.2 Product Information
3.7.3 Capacity Production Price Cost Production Value
3.7.4 Contact Information
3.8 Wright
3.8.1 Company Profile
3.8.2 Product Information
3.8.3 Capacity Production Price Cost Production Value
3.8.4 Contact Information
3.9 Medshape
3.9.1 Company Profile
3.9.2 Product Information
3.9.3 Capacity Production Price Cost Production Value
3.9.4

Read More
medicine

Drug (Medicine) Dispenser Market Evolving Technology, Segmentation and Industry Analysis 2015 to 2021

The MarketWatch News Department was not involved in the creation of this content.

New York, United States, Sat, 31 Oct 2020 08:34:44 / Comserve Inc. / — Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispensermarket is expected to reach at notable revenue by the end of 2021

The global drug (medicine) dispensermarket is segmented into application such as hospitals, pharmacies and homecare. Among these segments, homecare segment is expected to grow at maximum pace during the forecast period. The rise of the homecare segment is backed by the increasing demand for drug (medicine) dispenserby patients who have to response to drugs on daily basis and especially by patientswho have memory deficiencies. However, it can be used in hospitals and pharmacies also to reduce chances of medication error.

Global drug (medicine) dispenser market is expected to register a robust CAGR over the forecast period. Moreover, the global drug (medicine) dispensermarket is expected to reach at notable revenue by the end of 2021.Factor such as technological advancements in medical devices and increasing geriatric population across the globe are expected to be the dynamic factors behind the growth of this segment during the forecast period.

The North America segment by region accounted for major share of global drug (medicine) dispenser marketin 2015.Moreover, North America drug (Medicine) dispenser is poised to display substantial growth during the forecast period owing to a number of factors such as swelled disposable income, high spending on healthcare and increasing adoption of advanced medical devices in this region.

Download Sample of This Strategic Report @https://www.researchnester.com/sample-request-73

Increased Geriatric Population

Factors such as increasing older population and rising incidence of age-related memory weaknessare anticipated to fuel the demand for drug (medicine) dispenser over the forecast period.Furthermore, drug (medicine) dispenserhelps aged people to maintain their regular medication and avoid any medication error.This factor is envisioned to escalate the growth of Drug (Dispenser) Market in Future.

Technological Advancements in Medical Devices

Demand for automated medication dispensing systemis increasing due to its advantages such as prevention ofmedication error, easy controlling and better customization.Additionally, swift advancements in healthcare technologies and concerns regarding patient’s health and medication in hospitals is also increasing the demand for drug (medicine) dispenser in hospitals which in turn likely to foster the growth of global drug (medicine) dispenser market over the forecast period.

Although,high repair and maintenance cost of advanced medication dispenserand slow adoption rate in under developed countries are some of the factors that are likely to obstruct the growth of the drug (medicine) dispenser market in the near future.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Curious about this latest version of report? Obtain Report Details @https://www.researchnester.com/reports/global-drug-medicine-dispenser-market-analysis-opportunity-outlook-2021/73

This report also provides the existing competitive scenario of some of the key players of the global drug (medicine) dispensermarket which includes company profiling ofKoninklijke Philips N.V.,

Read More
medicine

A cure for COVID in your medicine cabinet? – Technology & Health

Lab testing (illustrative)
Lab testing (illustrative)

iStock

After all the billions of dollars invested into producing a vaccine for coronavirus, could it be that items most households already have in their medicine cabinets turn out to be all we need?

Two separate trials are currently underway to test mouthwash and aspirin for their role in protecting against Covid-19, and hopes are high that the results will show that treatment for this disease can be both cheap and effective.

Unilever is funding the trial into use of mouthwash, even though the product currently being tested, Dentyl, is not one of its own manufacture. According to scientists involved in the study, it has already been proven that one of the common ingredients of mouthwash, cetylpyridinium chloride, can kill 99.9% of bacteria and pathogens in a person’s mouth. Given that coronavirus appears to be primarily transmitted via saliva, this is a highly significant finding.

Professor Valerie O’Donnell of Cardiff University, where part of the trial is being conducted, told The Telegraph that results from the studies already conducted on other brands of mouthwash “are highly encouraging [even though] in vivo [i.e. human] studies have not been published … Recent studies in test tubes have as much as possible tried to mimic the conditions in the throat, but of course this isn’t the same as in vivo.”

The results of the study are due to be published within the next few months.

Meanwhile, another study is looking into the potential role of aspirin in combating some of the most dangerous consequences of coronavirus infection – blood clots that can prove fatal.

Aspirin has long been used as a blood thinner, even though long-term use has been linked to kidney damage. However, its use in the short term is now being investigated by a team of researchers with the “Recovery Trial” program, one of the largest research projects in the United Kingdom.

People with coronavirus “seem to have hyper-reactive platelets which help stop bleeding which increases risk of blood clotting,” scientists involved in the trial stated.

Professor Peter Horby, co-chief investigator of the Recovery Trial, explained that, “We felt it was particularly important to add aspirin to the trial since there is a clear rationale for believing that it might be beneficial and it is safe, inexpensive, and widely available. We are looking for medicines for Covid-19 that can be used immediately by anyone, anywhere in the world. We do not know if aspirin is such a medicine but we will find out.”

Around 2,000 people have been enrolled in the randomized trial. Those in the active group will receive 150mg of aspirin per day, on top of the usual drug regimen; those in the control group will receive the usual regimen only.

Researchers from the Recovery Trial were the first to prove the benefits of using dexamethasone, a cheap and widely available steroid, for coronavirus treatment. They are also currently testing use of plasma from recovered patients, and the “Regeneron” antibody cocktail that was used to

Read More
health

Consensus Guidelines Address Inpatient Diabetes Technology

A new consensus statement offers detailed guidelines for inpatient use of continuous glucose monitors (CGM) and automated insulin delivery (AID) systems.

Aimed at clinicians, researchers, and hospital administrators, the open-access document was recently published by a multidisciplinary international panel of 24 experts in the Journal of Diabetes Science and Technology.

The statement includes 77 separate recommendations under five headings: 1) continued use of CGM by patients already using them at home, 2) initiation of CGM in hospital, 3) continuation of AID systems in hospital by patients already using them at home, 4) logistics and hands-on care of hospitalized patients using CGM and AID systems, and 5) data management of CGM and AID systems in hospital.

“This is the most comprehensive and up-to-date guideline on the use of diabetes technology in the hospital now,” lead author Rodolfo J. Galindo, MD, told Medscape Medical News in an interview.

“Overall, most experts believe that CGM and AID have the potential to overcome the current limitations of glycemic monitoring in the hospital to improve patient outcomes but we need research, first to get the approval and second to get widespread use,” said Galindo, medical chair of the hospital diabetes taskforce at Emory Healthcare System, Atlanta, Georgia. 

COVID-19 Changed Everything

The guideline is an update of a 2017 statement on hospital use of CGM. The new guideine adds AID systems — sometimes referred to as an artificial pancreas, which combines a CGM and insulin pump and uses an algorithm to guide insulin delivery — and is the first to be developed during the COVID-19 era.

The update had been planned prior to the pandemic, but the actual panel meeting took place in April 2020, after the US Food and Drug Administration allowed inpatient use of CGM despite lack of official approval.

“COVID-19 changed everything…We had to be more specific about how to implement CGM in these patients. The standard of care is hourly point-of-care glucose monitoring in the [ICU], and at least every 4 hours outside the ICU. With limited [personal protective equipment] and the burden on nursing it was unachievable,” Galindo explained.

In June 2020, Galindo and other guideline authors developed a COVID-19-specific document (also open-access), which goes more into detail about CGM and how to implement in-hospital use during the pandemic.

The current consensus guideline “provides a high-level review of the evidence by experts,” Galindo added.

Recommendations Cover Different Technologies and Hospital Settings

The panel “strongly” advises that hospital providers consult with an inpatient diabetes team, if available, to help manage patients already using CGM prior to admission. Among other recommendations, they list several situations in which CGM data should not be relied upon for management decisions, including severe hyper- or hypoglycemia, diabetic ketoacidosis, or in patients with skin infections near the sensor site.

The panel also call for more research into outcomes for CGM continuation in the hospital and optimal implementation of both CGM and point-of-care glucose testing. For hospitals, strong recommendations include developing standard CGM data reports and

Read More